المؤلفون: Verboon C., Van Den Berg B., Cornblath D. R., Venema E., Gorson K. C., Lunn M. P., Lingsma H., Van Den Bergh P., Harbo T., Bateman K., Pereon Y., Sindrup So. H., Kusunoki S., Miller J., Islam Z., Hartung H. -P., Chavada G., Jacobs B. C., Hughes R. A. C., Van Doorn P. A. J. M. Addington, MD (University of Virginia, Charlottesville USA), S. Consortia. Protected by copyright. on October 7, 2019 at Uppsala Universitet BIBSAM http://jnnpTest. bmj. com/ J Neurol Neurosurg Psychiatry: first published as 10. 1136/jnnp-2019-321496 on 5 October 2019. Downloaded from 8 Verboon C, J Neurol Neurosurg Psychiatry 2019, 0:1–9. doi:10. 1136/jnnp-2019-321496 Neuromuscular Ajroud-Driss, MD (Northwestern University Feinberg, Chicago USA), G. Antonini, MD (Mental Health and Sensory Organs (NESMOS), Sapienza University, Sant’Andrea Hospital, Rome Italy), S. Attarian, MD, PhD (CHU Timone, Marseille France), F. A. Barroso, MD (Instituto de Investigaciones Neurológicas Raúl Carrea, FLENI, Buenos Aires, Argentina), L. Benedetti, PhD (Ospedale Sant’ Andrea La Spezia, La Spezia, Italy), T. E. Bertorini, MD (The University of Tennessee Health Science Center (UTHSC), Memphis USA), T. H. Brannagan, MD (Columbia University, New York City, USA), C. Briani, MD (University of Padova, Padova Italy), R. Bhavaraju-Sanka, MD (University Hospital/University of Texas Health Science Center, San Antonio Texas, S. Butterworth, MD (Pinderfields Hospital, Wakefield UK), C. Casasnovas, PhD (Bellvitge University Hospital – IDIBELL Neurometabolic Diseases Group. CIBERER, Barcelona Spain), G. Cavaletti, MD (University Milano-Bicocca, Monza Italy), S. Chen, PhD (Rutgers, Robert Wood Johnson University Hospital, New Brunswick, K. G. Claeys, PhD (1. University Hospitals Leuven, Leuven Belgium, 2. KU Leuven, Leuven Belgium), J. S. Cosgrove, MD (Leeds General Infirmary, Leeds UK), A. Davidson, MD (University of Glasgow, Glasgow UK), E. Dardiotis, MD (University of Thessaly, Hospital of Larissa, Larissa Greece), C. Dornonville de la Cour, MD (National Hospital Copenhagen, Copenhagen Denmark), C. G. Faber, PhD (Maastricht University Medical Centre, Maastricht, The Netherlands), T. E. Feasby, MD (University of Calgary, Calgary Canada), T. Fujioka, MD (Toho University Medical Center, Tokyo Japan), G. Galassi, MD (University Hospital of Modena, Modena Italy), J. M. Gilchrist, MD (Soulthern Illinois University School of Medicine, Springfield USA), N. A. Goyal, MD (University of California, Irvine USA), V. Granit, MD (Montefiore Medical, Center, New York, G. Gutiérrez-Gutiérrez, MD (Hospital Universitario Infanta Sofia, San Sebastian, Spain), R. D. M. Hadden, PhD (King’s College Hospital, London UK), J. K. L. Holt, PhD, FRCP (The Walton Centre, Liverpool UK), M. Htut, MD (St. George’s Hospital, I. Jericó Pascual, PhD (Complejo Hospitalario de Navarra, Pamplona Spain), S. Karafiath, MD (University of Utah School of Medicine, Salt Lake City, H. D. Katzberg, MD (University of Toronto, Toronto Canada), L. Kiers, MD (University of Melbourne, Royal Melbourne Hospital, Parkville Australia), B. C. Kieseier, MD (Heinrich Heine University, Düsseldorf Germany), K. Kimpinski, MD (University Hospital, LHSC London-Ontario, Canada), S. Kuwabara, PhD (Chiba University, Chiba Japan), J. Y. Kwan, MD (University of Maryland School of Medicine, Baltimore USA), S. S. Ladha, MD (Barrow Neurology Clinics, Phoenix Arizona, V. Lawson, MD (Wexner Medical Center at The Ohio State University, Columbus USA), H. Lehmann, PhD (University Hospital of Cologne, Universitätsklinikum Köln, Cologne Germany), H. Manji, FRCP (Ipswich Hospital, Ipswich UK), G. A. Marfia, MD (Neurological Clinic, Policlinico Tor Vergata, C. Márquez Infante, MD (Hospital Universitario Virgen del Rocio, Seville Spain), M. G. Mattiazzi, MD (Hospital Militar Central, C. J. McDermott, MD (Royal Hallamshire Hospital, NIHR Clinical, Sheffield UK), M. S. Monges, MD (Hospital de Pediatría J. P. Garrahan, G. Morís de la Tassa, MD (Hospital Universitario Central de Asturias, Asturias Spain), C. Nascimbene, PhD (Luigi Sacco Hospital, Milan Italy), E. Nobile Orazio, PhD (Milan University, Humanitas Clinicala and Research Institute Milan, R. J. Nowak, MD (Yale University School of Medicine, New Haven, M. Osei-Bonsu (James Cook University Hospital, Middlesbrough UK), J. Pardo Fernandez (Hospital Clínico de Santiago, Santiago de Compostela (A Coruña), L. Querol Gutierrez, PhD (Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, R. Reisin (Hospital Britanico, S. Rinaldi, MBChB, PhD (University of Oxford R. C. Roberts, MD (Addenbrooke’s Hospital Cambridge, Cambridge UK), I. Rojas-Marcos, MD (Hospital Univesitario Reina Sofia, Cordoba Spain), S. A. Rudnicki, MD (University of Arkansas, Fayetteville USA), A. Schenone, PhD (1. Department of Neurosciences, Rehabilitation Ophthalmology, Genetics and Maternal and Infantile Sciences (DINOGMI), University of Genova, Genova, Italy 2. IRCCS Policlinico San Martino, Genova Italy), M. J. Sedano Tous, MD (Hospital Universitario Marques de Valdecilla, Santander Cantabria, N. Shahrizaila, MD (Neurology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Malaya), K. Sheikh, PhD (The University of Texas Health Science Center at Houston, Houston USA), N. J. Silvestri, MD (Buffalo General Medical Center, Buffalo NY, C. L. Sommer, MD (Universitätsklinikum Würzburg, Würzburg Germany), J. D. Varrato, DO (Lehigh Valley Health Network, Allentown USA), J. Verschuuren, PhD (Leiden University Medical Centre, Leiden, M. V. Vytopil, PhD (Tufts University School of Medicine Lahey Hospital W. Waheed, MD (University of Vermont Medical Center, Burlington USA), L. Zhou, PhD (Icahn School of Medicine at Mount Sinai, USA). Other collaborators were:U. A. Badrising, I. R. Bella, MD (University of Mass Medical School, Worcester USA), C. Bunschoten, PhD candidate (Erasmus University Medical Centre, Rotterdam, J. Bürmann, Universitätsklinikum des Saarlandes, Homburg Germany), M. Busby, Bradford UK), C. C. Chao, PhD (National Taiwan University Hospital, Taipei Taiwan), M. E. Conti, MD (University Hospital Clinicas, M. C. Dalakas, MD (1. Thomas Jefferson University, Philadelphia USA, 2. National and Kapodistrian University of Athens, Athens Greece), P. Van Damme, PhD (University Hospital Leuven, A. Doets, the Netherlands), G. W. van Dijk, MD (Canisius Wilhelmina Hospital, Nijmegen, M. M. Dimachkie, MD (University of Kansas Medical Center, Kansas City, K. Doppler, A. Echaniz-Laguna, MD (Hopital de Hautepierre, Strasbourgh France), F. Eftimov, PhD (Amsterdam University Medical Centre, Amsterdam, R. Fazio, MD (Scientific Institute San Raffaele, C. Fokke, MD (Gelre Hospital, Zutphen and Apeldoorn, E. A. Fulgenzi, MD (Hospital Cesar Milstein Buenos Aires, M. P. J. Garssen, PhD (Jeroen Bosch Hospital, ’s Hertogenbosch, Zaltbommel and Drunen, C. J. Gijsbers, MD (Vlietland Hospital, Schiedam, J. Gilhuis, PhD (Reinier de Graaf Gasthuis, Delft, A. Grapperon, MD (CHU Timone, S. T. Hsieh, I. Illa, B. Islam, PhD (International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b) Dhaka, Bangladesh), K. Jellema, PhD (Haaglanden Medisch Centrum, The Hague, K. Kaida, PhD (National Defense Medical College, Saitama Japan), N. Kokubun, MD (Dokkyo Medical University, Tochigi Japan), N. Kolb, MD (University of Vermont, Burlington VT, R. van Koningsveld, PhD (Elkerliek Hospital, Helmond and Deurne, A. J. van der Kooi, K. Kuitwaard, PhD (Albert Schweitzer Hospital, Dordrecht, L. Landschoff Lassen, MD (Glostrup Hospital, Glostrup Denmark), S. E. Leonhard, M. Mandarakas, PhD (Erasmus University Medical Centre, E. Martinez Hernandez, MD (Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Q. D. Mohammad, PhD (National Institute of Neurosciences and Hospital, Dhaka Bangladesh), M. Pulley, MD (University of Florida, Jacksonville USA), Y. A. Rajabally, PhD (Queen Elizabeth Hospital, Birmingham UK), S. W. Reddel, PhD (Concord Repatriation General Hospital, Sydney Australia), T. van der Ree, MD (Westfriesgasthuis, Hoorn, J. Roodbol, G. M. Sachs, MD (University of Rhode Island, Providence USA), J. P. A. Samijn, PhD (Maasstad Hospital, L. Santoro, PhD (University Federico II, Napels Italy), B. Stein, MD (St. Joseph’s Regional Medical Center, Paterson USA), F. H. Vermeij, MD (Franciscus Gasthuis, L. H. Visser, PhD (Elisabeth-TweeSteden Hospital, Tilburg and Waalwijk, H. J. Willison, PhD (University of Glasgow, P. Wirtz, PhD (HagaZiekenhuis, S. A. Zivkovich, PhD (University of Pittsburgh Medical Center, Pittsburgh USA).

المساهمون: C., Verboon, B., Van Den Berg, D. R., Cornblath, E., Venema, K. C., Gorson, M. P., Lunn, H., Lingsma, P., Van Den Bergh, T., Harbo, K., Bateman, Y., Pereon, So. H., Sindrup, S., Kusunoki, J., Miller, Z., Islam, H. -P., Hartung, G., Chavada, B. C., Jacob, R. A. C., Hughe, Addington, Van Doorn P. A. J. M., (University of Virginia, Md, USA), Charlottesville, on October 7, S. Consortia. Protected by copyright., Downloaded from 8 Verboon C, 2019 at Uppsala Universitet BIBSAM http://jnnpTest. bmj. com/ J Neurol Neurosurg Psychiatry: first published as 10. 1136/jnnp-2019-321496 on 5 October 2019., J Neurol Neurosurg Psychiatry 2019, 1136/jnnp-2019-321496 Neuromuscular Ajroud-Driss, 0:1–9. doi:10., (Northwestern University Feinberg, Md, USA), Chicago, Antonini, G., (Mental Health and Sensory Organs (NESMOS), Md, University, Sapienza, Hospital, Sant’Andrea, Italy), Rome, Attarian, S., Md, (CHU Timone, Phd, France), Marseille, Barroso, F. A., (Instituto de Investigaciones Neurológicas Raúl Carrea, Md, Fleni, Aires, Bueno, Argentina), Benedetti, L., (Ospedale Sant’ Andrea La Spezia, Phd, Spezia, La, Italy), Bertorini, T. E., (The University of Tennessee Health Science Center (UTHSC), Md, USA), Memphi, Brannagan, T. H., (Columbia University, Md, York City, New, USA), Briani, C., (University of Padova, Md, Italy), Padova, Bhavaraju-Sanka, R., (University Hospital/University of Texas Health Science Center, Md, Antonio Texas, San, Butterworth, S., (Pinderfields Hospital, Md, UK), Wakefield, Casasnovas, C., Ciberer, PhD (Bellvitge University Hospital – IDIBELL Neurometabolic Diseases Group., Spain), Barcelona, Cavaletti, G., (University Milano-Bicocca, Md, Italy), Monza, Chen, S., (Rutgers, Phd, Wood Johnson University Hospital, Robert, Brunswick, New, Claeys, K. G., University Hospitals Leuven, PhD (1., Belgium, Leuven, KU Leuven, 2., Belgium), Leuven, Cosgrove, J. S., (Leeds General Infirmary, Md, UK), Leed, Davidson, A., (University of Glasgow, Md, UK), Glasgow, Dardiotis, E., (University of Thessaly, Md, of Larissa, Hospital, Greece), Larissa, Dornonville de la Cour, C., (National Hospital Copenhagen, Md, Denmark), Copenhagen, Faber, C. G., (Maastricht University Medical Centre, Phd, Maastricht

مصطلحات موضوعية: guillain-barré syndrome, poor prognosi, second ivig course, treatment, adult, aged, disability evaluation, female, guillain-barre syndrome, human, immunoglobulin g, immunoglobulin, intravenou, immunologic factor, male, middle aged, prognosi, time factor, treatment outcome, drug administration schedule

الوصف: Objective To compare disease course in patients with Guillain-Barré syndrome (GBS) with a poor prognosis who were treated with one or with two intravenous immunoglobulin (IVIg) courses. Methods From the International GBS Outcome Study, we selected patients whose modified Erasmus GBS Outcome Score at week 1 predicted a poor prognosis. We compared those treated with one IVIg course to those treated with two IVIg courses. The primary endpoint, the GBS disability scale at 4 weeks, was assessed with multivariable ordinal regression. Results Of 237 eligible patients, 199 patients received a single IVIg course. Twenty patients received an α early' second IVIg course (1-2 weeks after start of the first IVIg course) and 18 patients a α late' second IVIg course (2-4 weeks after start of IVIg). At baseline and 1 week, those receiving two IVIg courses were more disabled than those receiving one course. Compared with the one course group, the adjusted OR for a better GBS disability score at 4 weeks was 0.70 (95%CI 0.16 to 3.04) for the early group and 0.66 (95%CI 0.18 to 2.50) for the late group. The secondary endpoints were not in favour of a second IVIg course. Conclusions This observational study did not show better outcomes after a second IVIg course in GBS with poor prognosis. The study was limited by small numbers and baseline imbalances. Lack of improvement was likely an incentive to start a second IVIg course. A prospective randomised trial is needed to evaluate whether a second IVIg course improves outcome in GBS.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31586949; info:eu-repo/semantics/altIdentifier/wos/WOS:000508888700002; volume:91; issue:2; firstpage:1; lastpage:9; numberofpages:9; journal:JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY; http://hdl.handle.net/11573/1509595Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85073171517

الإتاحة: https://doi.org/10.1136/jnnp-2019-321496Test
http://hdl.handle.net/11573/1509595Test

المؤلفون: Willeke F, Westendorp, Elles, Zock, Jan-Dirk, Vermeij, Henk, Kerkhoff, Paul J, Nederkoorn, Marcel G W, Dijkgraaf, Diederik, van de Beek, F H, Vermeij

المساهمون: Center of Experimental and Molecular Medicine, Neurology, Graduate School, Epidemiology and Data Science, APH - Methodology, ACS - Atherosclerosis & ischemic syndromes

المصدر: Neurology, 90(18), e1553-e1560. Lippincott Williams and Wilkins

مصطلحات موضوعية: medicine.medical_specialty, Cost effectiveness, Cost-Benefit Analysis, law.invention, 03 medical and health sciences, 0302 clinical medicine, Cost of Illness, Randomized controlled trial, law, Modified Rankin Scale, Internal medicine, medicine, Humans, 030212 general & internal medicine, Stroke, Aged, business.industry, Standard treatment, Ceftriaxone, Health Care Costs, Middle Aged, medicine.disease, Confidence interval, Anti-Bacterial Agents, Quality-adjusted life year, Treatment Outcome, Quality-Adjusted Life Years, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug

الوصف: ObjectiveTo evaluate the cost-effectiveness of preventive ceftriaxone vs standard stroke unit care without preventive antimicrobial therapy in acute stroke patients.MethodsIn this multicenter, randomized, open-label trial with masked endpoint assessment, 2,550 patients with acute stroke were included between 2010 and 2014. Economic evaluation was performed from a societal perspective with a time horizon of 3 months. Volumes and costs of direct, indirect, medical, and nonmedical care were assessed. Primary outcome was cost per unit of the modified Rankin Scale (mRS) and per quality-adjusted life year (QALY) for cost-effectiveness and cost-utility analysis. Incremental cost-effectiveness analyses were performed.ResultsA total of 2,538 patients were available for the intention-to-treat analysis. For the cost-effectiveness analysis, 2,538 patients were available for in-hospital resource use and 1,453 for other resource use. Use of institutional care resources, out-of-pocket expenses, and productivity losses was comparable between treatment groups. The mean score on mRS was 2.38 (95% confidence interval [CI] 2.31–2.44) vs 2.44 (95% CI 2.37–2.51) in the ceftriaxone vs control group, the decrease by 0.06 (95% CI −0.04 to 0.16) in favor of ceftriaxone treatment being nonsignificant. However, the number of QALYs was 0.163 (95% CI 0.159–0.166) vs 0.155 (95% CI 0.152–0.158) in the ceftriaxone vs control group, with the difference of 0.008 (95% CI 0.003–0.012) in favor of ceftriaxone (p = 0.006) at 3 months. The probability of ceftriaxone being cost-effective ranged between 0.67 and 0.89. Probability of 0.75 was attained at a willing-to-pay level of €2,290 per unit decrease in the mRS score and of €12,200 per QALY.ConclusionsPreventive ceftriaxone has a probability of 0.7 of being less costly than standard treatment per unit decrease in mRS and per QALY gained.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe646a1003ce98595a17a63f7c9009d9Test
https://doi.org/10.1212/wnl.0000000000005412Test

المؤلفون: B. C. Jacobs, B. van den Berg, C. Verboon, G. Chavada, D. R. Cornblath, K. C. Gorson, T. Harbo, H. Hartung, R. A. . C. Hughes, S. Kusunoki, P. A. van Doorn, H. J. Willison, R. A. C. Hughes, H. P. Hartung, M. van Woerkom, J. Roodbol, R. C. Reisin, S. W. Reddel, Z. Islam, B. Islam, Q. D. Mohammad, P. van den Bergh, T. E. Feasby, Y. Z. Wang, Y. Péréon, H. C. Lehmann, E. Dardiotis, N. Shahrizaila, K. Bateman, I. Illa, L. A. Querol, S. T. Hsieh, A. Davidson, J. M. Addington, S. Ajroud Driss, H. Andersen, G. Antonini, S. Attarian, U. Badrising, F. A. Barroso, L. Benedetti, A. Beronio, M. Bianco, D. Binda, C. Briani, J. Bã1⁄4rmann, I. R. Bella, T. E. Bertorini, R. Bhavaraju Sanka, T. H. Brannagan, M. Busby, S. Butterworth, M. Campagnolo, C. Casasnovas, G. Cavaletti, C. S. Chao, S. Chen, S. Chetty, K. G. Claeys, J. A. Cohen, M. E. Conti, J. S. Cosgrove, M. C. Dalakas, M. M. Dimachkie, U. Dillmann, C. Domínguez González, K. Doppler, C. Dornonville de la Cour, A. Echaniz Laguna, F. Eftimov, C. G. Faber, R. Fazio, C. Fokke, T. Fujioka, E. A. Fulgenzi, G. Galassi, T. Garcia, M. Garnero, M. P. J. Garssen, C. J. Gijsbers, J. M. Gilchrist, H. J. Gilhuis, J. M. Goldstein, N. Goyal, V. Granit, A. Grapperon, G. Gutiérrez Gutiérrez, L. Gutmann, R. D. M. Hadden, J. V. Holbech, J. K. L. Holt, C. Homedes Pedret, M. Htut, K. Jellema, I. Jericó Pascual, K. Kaida, S. Karafiath, H. D. Katzberg, L. Kiers, B. C. Kieseier, K. Kimpinski, R. P. Kleyweg, N. Kokubun, N. A. Kolb, K. Kuitwaard, S. Kuwabara, J. Y. Kwan, S. S. Ladha, L. Landschoff Lassen, V. Lawson, D. Ledingham, L. León Cejas, C. A. Luciano, S. T. Lucy, M. P. T. Lunn, A. Magot, H. Manji, C. Marchesoni, G. A. M. Marfia, C. Márquez Infante, E. Martinez Hernandez, G. Mataluni, M. Mattiazi, C. J. Mcdermott, G. D. Meekins, J. Miller, M. S. Monges, M. C. J. Montero, G. Morís de la Tassa, C. Neumann, R. J. Nowak, P. Orizaola Balaguer, M. Osei Bonsu, E. B. L. Pan, J. Pardo Fernandez, M. Pasnoor, M. T. Pulley, Y. A. Rajabally, S. Rinaldi, C. Ritter, R. C. Roberts, I. Rojas Marcos, S. A. Rudnicki, G. M. Sachs, J. P. A. Samijn, L. Santoro, D. S. Saperstein, A. Savransky, H. Schneider, A. Schenone, M. J. Sedano Tous, Y. Sekiguchi, K. A. Sheikh, N. J. Silvestri, S. H. Sindrup, C. L. Sommer, B. Stein, A. M. Stino, A. Spyropoulos, J. Srinivasan, H. Suzuki, S. W. Taylor, H. Tankisi, D. Tigner, P. T. Twydell, F. Valzania, P. van Damme, A. J. van der Kooi, G. W. van Dijk, T. van der Ree, R. van Koningsveld, J. D. Varrato, F. H. Vermeij, J. J. G. M. Verschuuren, L. H. Visser, M. V. Vytopil, W. Waheed, M. Wilken, C. Wilkerson, P. W. Wirtz, Y. Yamagishi, E. M. Yiu, L. Zhou, S. Zivkovic, E. Nobile-Orazio, C. Nascimbene

المساهمون: B.C. Jacob, B. van den Berg, C. Verboon, G. Chavada, D.R. Cornblath, K.C. Gorson, T. Harbo, H. Hartung, R.A.C. Hughe, S. Kusunoki, P.A. van Doorn, H.J. Willison, H.P. Hartung, M. van Woerkom, J. Roodbol, R.C. Reisin, S.W. Reddel, Z. Islam, B. Islam, Q.D. Mohammad, P. van den Bergh, T.E. Feasby, Y.Z. Wang, Y. Péréon, H.C. Lehmann, E. Dardioti, E. Nobile-Orazio, N. Shahrizaila, K. Bateman, I. Illa, L.A. Querol, S.T. Hsieh, A. Davidson, J.M. Addington, S. Ajroud-Dri, H. Andersen, G. Antonini, S. Attarian, U. Badrising, F.A. Barroso, L. Benedetti, A. Beronio, M. Bianco, D. Binda, C. Briani, J. Bã1⁄4rmann, I.R. Bella, T.E. Bertorini, R. Bhavaraju-Sanka, T.H. Brannagan, M. Busby, S. Butterworth, M. Campagnolo, C. Casasnova, G. Cavaletti, C.S. Chao, S. Chen, S. Chetty, K.G. Claey, J.A. Cohen, M.E. Conti, J.S. Cosgrove, M.C. Dalaka, M.M. Dimachkie, U. Dillmann, C. Domínguez-González, K. Doppler, C. Dornonville de la Cour, A. Echaniz-Laguna, F. Eftimov, C.G. Faber, R. Fazio, C. Fokke, T. Fujioka, E.A. Fulgenzi, G. Galassi, T. Garcia, M. Garnero, M.P.J. Garssen, C.J. Gijsber, J.M. Gilchrist

مصطلحات موضوعية: biomarker, diagnosi, Guillain-Barré syndrome, outcome, prognosi, treatment, Neuroscience (all), Neurology (clinical), Settore MED/26 - Neurologia

الوصف: Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1-3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28406555; info:eu-repo/semantics/altIdentifier/wos/WOS:000403021600001; volume:22; issue:2; firstpage:68; lastpage:76; numberofpages:9; journal:JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM; http://hdl.handle.net/2434/524844Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85020274741

الإتاحة: https://doi.org/10.1111/jns.12209Test
http://hdl.handle.net/2434/524844Test

المؤلفون: J. M. Zuetenhorst, F. H. Vermeij, M. J. van den Bent, E. M. Rodenburg

المساهمون: Neurology

المصدر: Journal of Neurology, 264(6), 1281-1283. D. Steinkopff-Verlag

مصطلحات موضوعية: business.industry, Varicella zoster virus, medicine.disease, medicine.disease_cause, Virology, 03 medical and health sciences, 0302 clinical medicine, Neurology, 030220 oncology & carcinogenesis, medicine, Neurology (clinical), business, 030217 neurology & neurosurgery, Encephalitis, Neuroradiology, Solid Carcinoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aca7249581679e99681b8cf2bc2ab72Test
https://pure.eur.nl/en/publications/9c7ec2ce-98d4-4439-98de-22706a0b4a63Test